States Eye Expanded Drug Price Review Boards as Costs Rise

In response to rising drug prices, some states have launched prescription drug review boards designed to make medicines more affordable. So far, the boards control prices mainly for states’ Medicaid and state employee plans, but some states are considering whether to set up panels that would also work to set upper payment limits for prescription drugs in commercial insurance.

A new report by professional services firm Manatt found that 17 states so far have implemented or introduced legislation for boards that exercise some influence on drug prices, primarily in the realm of plans controlled by state governments — state Medicaid plans and commercial plans in which the state government is the plan sponsor. The report found that six states — Maine, Maryland, Massachusetts, New Hampshire, New York and Ohio — have such boards in place.

© 2023 MMIT
Peter Johnson

Peter Johnson

Peter has been a reporter for nearly a decade. Before joining AIS Health, Peter covered a wide variety of topics in his hometown of Seattle, where he continues to live. Peter’s work has appeared in publications including The Atlantic and The Stranger. Peter attended Colby College.

Related Posts

doctor-speaking-to-a-patient
May 25

Commercial Insurance Restrictions Complicate Biosimilar Adoption

READ MORE
shell-game
May 25

‘Shell Game’ or Rebate Maximizers? FTC Probe Reignites Debate Over GPOs

Read More
pills-in-hand
May 25

As Weight Loss Drugs’ Star Rises, Plan Sponsors, Researchers Worry About Costs

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today